Drug Delivery Nanoparticles in Skin Cancers

Abstract

Nanotechnology involves the engineering of functional systems at nanoscale, thus being attractive for disciplines ranging from materials science to biomedicine. One of the most active research areas of the nanotechnology is nanomedicine, which applies nanotechnology to highly specific medical interventions for prevention, diagnosis, and treatment of diseases, including cancer disease. Over the past two decades, the rapid developments in nanotechnology have allowed the incorporation of multiple therapeutic, sensing, and targeting agents into nanoparticles, for detection, prevention, and treatment of cancer diseases. Nanoparticles offer many advantages as drug carrier systems since they can improve the solubility of poorly water-soluble drugs, modify pharmacokinetics, increase drug half-life by reducing immunogenicity, improve bioavailability, and diminish drug metabolism. They can also enable a tunable release of therapeutic compounds and the simultaneous delivery of two or more drugs for combination therapy. In this review, we discuss the recent advances in the use of different types of nanoparticles for systemic and topical drug delivery in the treatment of skin cancer. In particular, the progress in the treatment with nanocarriers of basal cell carcinoma, squamous cell carcinoma, and melanoma has been reported.

Surface modification of MPEG-b-PCL-based nanoparticles via oxidative self-polymerization of dopamine for malignant melanoma therapy

“…Nanoparticles (NPs) represent promising drug vehicles, especially for specific delivery of anticancer agents to the tumor site, which could enhance the clinical effectiveness and reduce systemic toxic side effects. [9][10][11] The NPs used as drug vehicles have many important advantages, such as high encapsulation efficiency (EE) and drug-loading capacity, minor drug leakage, sustained release, and excellent feasibility of routes of administration. 12,13 Many chemotherapeutic drugs, such as docetaxel, puerarin, PTX, and doxorubicin, can be delivered by using NPs.…”

Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors

“…The unconfirmed ORR was 60% (9 PR, 2 SD, and 3 PD). Incorporation of nanoparticle systems may overcome toxicity associated with horizontal inhibition by targeting drug delivery to the tumor site at therapeutic levels while sparing the rest of the body from off-target toxicities (98,99). Polymeric micelles and liposome nanoparticles have been found to preferentially accumulate in solid tumors.…”

Untitled

“…In comparison to other transdermal and dermal delivery systems  The transethosomal system is passive, noninvasive and is available for immediate commercialization 8 .  It contains non-toxic raw materials in the formulation 8 .…”

“… It contains non-toxic raw materials in the formulation 8 .  Transethosomal drug delivery can be applied to many fields including veterinary and cosmetic fields.…”